What went wrong with CureVac's mRNA vaccine?
Abstract
Company blames variants of the coronavirus, but type of RNA may have been key.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The low vaccination dosage of CVnCoV and the use of unmodified nucleotides might have contributed to its performance in phase II clinical trials compared to licensed COVID-19 vaccines.
“The low vaccination dosage of CVnCoV and the use of unmodified nucleotides might have contributed to the performance of this vaccine in phase II clinical trials compared to the licensed COVID-19 vaccine.428”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [428]
Cited by
Sorted by citations
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823 · see citing works
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
“The low vaccination dosage of CVnCoV and the use of unmodified nucleotides might have contributed to the performance of this vaccine in phase II clinical trials compared to the licensed COVID19 vaccine.(428) On October 12, 2021, the European Medicines Agency (EMA) announced the suspension of the rolling review of CVnC…”
MethodChallenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371 · see citing works
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 177 · see citing works
Decoding pseudouridine: an emerging target for therapeutic development
Cerneckis, J., Cui, Q., He, C., Yi, C., & Shi, Y. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.008 · Cited by 155 · see citing works
Zhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 140 · see citing works
The immunostimulatory nature of mRNA lipid nanoparticles
Sharma, P., Hoorn, D., Aitha, A., Breier, D., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115175 · Cited by 132 · see citing works
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 106 · see citing works
Bernard, M., Bazin, E., Petiot, N., Lemdani, K., Commandeur, S., Verdelet, C., Margot, S., Perkov, V., Ripoll, M., Garinot, M., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.004 · Cited by 62 · see citing works
“32 June 2023 a 2023 The A This is an open access article under the CC BY-NC-ND license (http (47% effectiveness at preventing Covid-19 in phase 3 trials versus >93% for the licensed vaccines of Pfizer-BioNTech and Moderna).(2,4) While Curevac was able to improve its Covid-19 vaccine candidate to the level of marketed…”
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 32 · see citing works
“Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.”
BackgroundInfluentialLiana, D., & Phanumartwiwath, A. (2021) · Journal of Natural Medicines · doi:10.1007/s11418-021-01575-1 · Cited by 29 · see citing works
“, Pfizer [9] Moderna [10], ChulaCov19 [11], and Curevac [12]); DNA (e.”
BackgroundHajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 26 · see citing works
Clinical advancements in mRNA vaccines against viral infections
Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 25 · see citing works
Multifunctional rolling circle transcription-based nanomaterials for advanced drug delivery
Ma, X., Zhang, Y., Huang, K., Zhu, L., & Xu, W. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122241 · Cited by 24 · see citing works
Akelew, Y., Henok, A., Ebrahim, E., Atnaf, A., & Hailemichael, W. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.573 · Cited by 15 · see citing works
“deficient simian adenovirus expressing full‐length SARS‐CoV‐2 spike protein 70% efficacy In adults, >14 days after the 2nd dose.(103) One dose of vaccine provides 60%–70%”
BackgroundQuantitative profiling of pseudouridylation landscape in the human transcriptomePreprint
Zhang, M., Jiang, Z., Ma, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.25.513650 · Cited by 13 · see citing works
Wang, N., & Wang, T. (2024) · Biotechnology Journal · doi:10.1002/biot.202300658 · Cited by 10 · see citing works
“[118] InterimanalysisindicatesthatCVnCoV’smodestefficacymaybeowing to the newly emerged SARS-CoV2 variants, as only one of 124 cases was identified by sequencing to be caused by the ancestral strain, while 57% of the cases were confirmed with variants of concern.”
Sultana, A., Mim, S. R., Saha, A., Yesmin, F., Tahsin, M. R., Bahar, N. B., Fatema, K. R., Shahriar, S., Prattay, K. M. R., Rabbi, F., et al. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-25527-2 · Cited by 7 · see citing works
Electron attachment dynamics following UV excitation of iodide-2-thiouracil complexes
Koga, M., Asplund, M., & Neumark, D. M. (2022) · The Journal of Chemical Physics · doi:10.1063/5.0098280 · Cited by 6 · see citing works
Oktavianawati, I., Santoso, M., Bakar, M. F. A., Kim, Y., & Fatmawati, S. (2023) · Applied Biological Chemistry · doi:10.1186/s13765-023-00842-x · Cited by 5 · see citing works
“Based on previous studies, Curevac, which uses an unmodified RNA-based vaccine, has low efficacy [59], with an efficacy rate of only 47% against SARS-CoV-2 [60].”
MethodA Critical Assessment of COVID-19 Genomic Vaccines
Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 3 · see citing works
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19
Kole, E. B., Jadhav, K., Singh, R., Verma, R. K., Chatterjee, A., & Naik, J. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053265 · Cited by 1 · see citing works
Nievergelt, P. P., Berliat, F., McAuley, K. E., Dorgan, C. R., van Well, R. M., Thorn, A., & Spingler, B. (2024) · ChemMedChem · doi:10.1002/cmdc.202300600 · Cited by 3 · see citing works
Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation
Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2 · see citing works
Optimal ordering strategy and budget allocation for the Covid-19 vaccination planning
Liu, X., Zhu, S. Z., & Wang, J. (2024) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2024002
- Authors
- Cohen, J.
- Corresponding author
- Cohen, Jon
- ORCID
- Cohen, Jon
- Venue
- Science
- Published
- 2021-06-25
- Volume
- 372
- Issue
- 6549
- Pages
- 1381-1381
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3174443753
- Cited by
- 25
- References
- 0
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 3
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA vaccines, COVID-19 vaccines, SARS-CoV-2 variants, vaccine failure, lipid nanoparticle formulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
